Eleven Therapeutics
Eleven Therapeutics is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Eleven Therapeutics.
Eleven Therapeutics is a company.
Key people at Eleven Therapeutics.
Eleven Therapeutics is a biotechnology company developing next-generation RNA therapeutics, particularly siRNA treatments for respiratory diseases, by integrating AI, combinatorial chemistry, and advanced RNA biology.[1][2][3] Founded in 2020 and headquartered in Tel Aviv, Israel, with hubs in Cambridge (UK), Boston (US), and Tel Aviv, it targets unmet needs in antiviral prophylactics and non-infectious respiratory conditions, such as an intranasal siRNA for SARS-CoV-2 in preclinical stages.[1][2][3] The company's discovery engine combines bio-engineering, genomics, and machine learning to map vast RNA combinatorial spaces, transforming drug discovery into a programmable process while serving patients with high unmet medical needs.[2][3]
Eleven Therapeutics was established in 2020 by founders Shaun Ilan, Greg Hannon, and Erlich Yaniv, a cross-disciplinary team of entrepreneur-scientists from leading academic institutions, pharma companies, and military backgrounds.[1][3] The idea emerged amid a biological revolution—driven by massively parallel DNA synthesis, high-throughput sequencing, genomic discoveries, and machine learning—aiming to replace slow trial-and-error drug development with scalable RNA programming.[3] Early traction includes partnerships with top institutions like the NIAID Vaccine Research Center, Cambridge University, Twist Biosciences, and Biotage, plus a preclinical pipeline focused on respiratory diseases.[1][3]
Eleven Therapeutics rides the RNA therapeutics wave, amplified by post-COVID advances in mRNA vaccines and oligonucleotide drugs, leveraging AI and high-throughput technologies to accelerate beyond traditional trial-and-error methods.[2][3] Timing is ideal amid rising respiratory disease burdens—from pandemics to chronic conditions—where market forces like genomic data explosion and machine learning favor programmable, precise therapies over broad-spectrum drugs.[1][3] By partnering with institutions like NIAID and Cambridge University, it influences the ecosystem, pushing RNAi into scalable, next-gen applications and potentially reshaping biotech's approach to gene silencing for unmet needs.[3]
Eleven Therapeutics is poised to expand its preclinical pipeline into clinical stages, prioritizing respiratory antivirals and non-infectious treatments amid growing AI-biotech convergence.[1][2] Trends like advancing combinatorial chemistry and global health threats will propel its programmable platform, potentially yielding durable prophylactics and first-in-class therapies. Its influence may evolve by setting standards for AI-driven RNA design, drawing more partnerships and investment to solidify its role in precision medicine—ushering RNA technologies from revolution to routine.
Key people at Eleven Therapeutics.
